---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-25-000004"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T20:04:50.624783+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q3 revenue flat at $2.3M; gross margin expands to 64.1%

## Summary
- Nine-month gross profit $4.5M (+12.2% YoY); margin 64.1% vs 58.4%.
- Operating expenses down 34% to $11.1M; cash burn reduced 54.5% to $5.0M.
- Average unit price per test +7% YoY; sales per FTE up 167% in Q3.
- Shift to profitable revenue; OvaSuite adopted by large IDN for O-RADS 4 patients.
- Progress on ENDOinform endometriosis diagnostic; milestones toward commercial readiness.

## SEC filing metadata
- accession: 0000926617-25-000004
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661725000004/0000926617-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661725000004/awhl-20251114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-25-000004
- JSON: https://secwatch.observer/filing/0000926617-25-000004.json
- Plain text: https://secwatch.observer/filing/0000926617-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.